Abstract
In a series of 61 consecutive patients undergoing heart, heart and lung, and lung transplantation, 24 patients were known to be cytomegalovirus (CMV) antibody negative on the day of transplantation. Enzyme linked immunosorbent assays (ELISA) for CMV IgG were performed on donor samples on the day of operation. In 16 of the 24 susceptible patients the test was negative and the only preventive measure taken was the use of blood and blood products from CMV-antibody negative blood donors. None of these patients acquired primary infection with CMV. In another six patients the donor serum was found to contain CMV specific IgG, and in these patients, including one heart and lung transplant recipient, prophylaxis with CMV specific hyperimmune globulin was given. All six patients developed CMV IgM antibodies and in five there was an associated but clinically mild illness. None of these patients required treatment. In the remaining two patients ELISA tests on the donor sera gave equivocal results and hyperimmune globulin was withheld. Both patients developed primary CMV infection of greater severity than those given hyperimmune globulin and one required treatment. Reference tests confirmed that the donor sera contained CMV antibodies. Primary CMV infection in susceptible patients after heart transplantation can be avoided by the use of screened blood and blood products where the organ donor is seronegative to CMV and it can be improved by the use of prophylactic hyperimmune globulin where the donor is CMV antibody positive.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Glenn J. Cytomegalovirus infections following renal transplantation. Rev Infect Dis. 1981 Nov-Dec;3(6):1151–1178. doi: 10.1093/clinids/3.6.1151. [DOI] [PubMed] [Google Scholar]
- Mackinnon S., Burnett A. K., Crawford R. J., Cameron S., Leask B. G., Sommerville R. G. Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation. J Clin Pathol. 1988 Sep;41(9):948–950. doi: 10.1136/jcp.41.9.948. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pak C. Y., Eun H. M., McArthur R. G., Yoon J. W. Association of cytomegalovirus infection with autoimmune type 1 diabetes. Lancet. 1988 Jul 2;2(8601):1–4. doi: 10.1016/s0140-6736(88)92941-8. [DOI] [PubMed] [Google Scholar]
- Schäfers H. J., Haverich A., Wahlers T., Milbradt H., Flik J., Fieguth H. G., Borst H. G. Cytomegalovirus prophylaxis after heart transplantation using specific hyperimmunoglobulin. Transplant Proc. 1987 Oct;19(5):4061–4062. [PubMed] [Google Scholar]
- Smiley M. L., Wlodaver C. G., Grossman R. A., Barker C. F., Perloff L. J., Tustin N. B., Starr S. E., Plotkin S. A., Friedman H. M. The role of pretransplant immunity in protection from cytomegalovirus disease following renal transplantation. Transplantation. 1985 Aug;40(2):157–161. doi: 10.1097/00007890-198508000-00010. [DOI] [PubMed] [Google Scholar]
- Snydman D. R., Werner B. G., Heinze-Lacey B., Berardi V. P., Tilney N. L., Kirkman R. L., Milford E. L., Cho S. I., Bush H. L., Jr, Levey A. S. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987 Oct 22;317(17):1049–1054. doi: 10.1056/NEJM198710223171703. [DOI] [PubMed] [Google Scholar]
- Stirk P. R., Griffiths P. D. Use of monoclonal antibodies for the diagnosis of cytomegalovirus infection by the detection of early antigen fluorescent foci (DEAFF) in cell culture. J Med Virol. 1987 Apr;21(4):329–337. doi: 10.1002/jmv.1890210405. [DOI] [PubMed] [Google Scholar]
- Wreghitt T. G., Hakim M., Gray J. J., Kucia S., Wallwork J., English T. A. Cytomegalovirus infections in heart and heart and lung transplant recipients. J Clin Pathol. 1988 Jun;41(6):660–667. doi: 10.1136/jcp.41.6.660. [DOI] [PMC free article] [PubMed] [Google Scholar]